Articles tagged with Monoclonal Antibodies
A human monoclonal antibody, ZIKV-117, has been isolated that 'neutralizes' the Zika virus in a mouse model and protects against fetal damage. The findings may aid development of an effective anti-Zika vaccine.
Site-specific conjugation technologies have enabled the development of next-generation homogeneous antibody-drug conjugates with superior stability and therapeutic index. These advancements promote the use of ADCs as a new therapeutic option for cancer patients.
A Phase II clinical trial has shown an 80% success rate in shrinking tumors in newly diagnosed, high-risk neuroblastoma patients treated with a new monoclonal antibody. The experimental agent was found to have reduced treatment-limiting pain compared to other anti-GD2 monoclonal antibodies.
Researchers have successfully developed a new treatment for the deadly Junin virus, providing complete protection against the disease. The laboratory-engineered antibody demonstrated effectiveness in guinea pigs and showed promise as a therapeutic solution for patients.
Vanderbilt researchers have identified a new antibody treatment for H7 avian flu with remarkable neutralizing potency, potentially offering short-term protection to people exposed or infected by the virus. The antibodies were isolated from human monoclonal antibodies generated in response to an experimental bird flu vaccine.
Researchers discovered two potent Ebola antibodies that eliminate symptoms in just five days after infection. The monoclonal antibodies target different regions of the virus's glycoprotein and work by interfering with its entry into host cells.
Scientists have developed a new class of monoclonal antibodies that target misfolding proteins in neurodegenerative diseases. The antibodies successfully reverse damage to brain tissue in animals, suggesting a potential therapeutic agent for Alzheimer's and Parkinson's diseases.
Researchers have determined the structure of a human monoclonal antibody that strongly neutralizes a type of the potentially lethal dengue virus in an animal model. This finding could lead to effective therapies and vaccines against dengue, a complex of four distinct mosquito-borne viruses causing illness and death in the tropics.
A phase III clinical trial shows necitumumab significantly improves median overall survival in stage IV squamous non-small cell lung cancer patients. The drug's 'fully human' EGFR antibody approach demonstrates potential as a novel immunotherapy strategy.
Researchers explored the efficacy of biosimilar monoclonal antibody CT-P13 in treating rheumatic diseases, including its similarities and differences with the reference drug infliximab. The study found that CT-P13 is almost identical to infliximab and has similar immunogenicity, but more real-world data are needed on switchability.
Researchers at NIST have developed a precise method to measure the structural configuration of monoclonal antibodies using two-dimensional nuclear magnetic resonance (2D NMR) spectroscopy. This technique allows for high-resolution spectral analysis, enabling the determination of whether protein folding is occurring as desired, and pote...
The Beth Israel Deaconess Medical Center will conduct proof-of-concept studies in monkeys and launch Phase 1 and Phase 2 clinical trials to test broadly neutralizing monoclonal antibodies. The goal is to suppress or eradicate HIV in humans, providing an alternative to antiretroviral therapies.
A randomized trial of 101 patients with chronic obstructive pulmonary disease found that benralizumab had no effect on acute exacerbation rates. However, subgroup analyses indicate the need for further investigation into the use of benralizumab in patients with COPD and eosinophilia.
The Festschrift issue honors Dr. Koprowski's pioneering work on vaccines, including the oral polio vaccine, and its impact on cancer biology research. Dr. Koprowski's achievements have been recognized by CASIS, which enabled visionaries to explore life science research in microgravity environments.
New research reveals that macrophage populations mediate tumor cell removal following monoclonal antibody treatment. Additionally, targeting the p57Kip2 pathway in adults with type 2 diabetes may improve β cell function and expand β cell mass.
Researchers found that macrophage populations actively phagocytose tumor cells following monoclonal antibody treatment. Optimized therapies may enhance macrophage recruitment and activity to improve removal of circulating tumor cells in cancer patients.
Researchers have discovered that monoclonal antibodies can effectively treat HIV by directly targeting free virus and virally infected cells. The treatment resulted in rapid decline of virus levels in monkeys and boosted their immune responses against the virus, offering a potential new therapy option for humans.
Researchers at University of California, San Diego Moores Cancer Center identified a humanized monoclonal antibody targeting CD44, directly killing chronic lymphocytic leukemia (CLL) cells. The antibody, RG7356, induces apoptosis in CLL cells expressing ZAP-70, a protein found in roughly half of CLL patients.
A new Ebola virus study demonstrates a proof-of-concept for using monoclonal antibodies to prevent lethal disease in rhesus macaques. The plant-based production method offers potential for an economical and effective medical countermeasure.
In a preliminary human trial, an injection targeting PCSK9, a cholesterol regulator, lowered low-density lipoprotein (LDL) or 'bad' cholesterol by 64% in healthy volunteers. The study found that increasing doses of the monoclonal antibody AMG145 improved cholesterol levels and reduced side effects.
A human monoclonal antibody significantly suppressed hepatitis C virus (HCV) levels in liver transplant patients, delaying viral rebound. The treatment also reduced HCV-related liver damage and improved patient outcomes.
Researchers at Singapore Immunology Network (SIgN) and VIVALIS have developed two fully human monoclonal antibodies that can neutralize several Chikungunya strains. These antibodies, generated using VIVALIS' Humalex platform, show promise as a potential treatment for the disease.
A new monoclonal antibody, RAB-1, has shown promising results in a Phase 1 study, achieving protective antibody levels comparable to the current standard of treatment. The therapy could potentially save tens of thousands of lives annually by addressing supply problems and side-effect issues associated with human rabies immune globulin.
Researchers at Genentech Inc. developed a way to specifically eliminate IgE-producing B cells, providing a new approach to treating asthma and other allergic diseases. The monoclonal antibody neutralizes the effects of soluble IgE molecules in the blood, reducing their levels and numbers.
The RECAN project developed novel fluorochrome dyes bound to monoclonal antibodies, enabling improved diagnosis of leukaemia and rheumatic diseases. The project also produced recombinant proteins for immunisation and created a range of specific monoclonal and polyclonal antibodies with great commercial potential.
Researchers at Tufts University developed a novel antitoxin strategy using 'tagged binding agents' that can bind to Botulinum toxin molecules and flush them out of the system. This approach has the potential to create more efficient therapies against toxins used in bioterrorist events, snake bites, and chronic diseases.
Scientists successfully produced plant-based monoclonal antibodies that effectively combat West Nile virus infections, rivaling their mammalian cell counterparts. The production technique holds promise for making life-saving treatments more affordable in resource-constrained regions.
A combination of two fully human monoclonal antibodies shown to reduce Clostridium difficile (C. difficile) infection recurrence by 72%. The treatment resulted in a significant reduction in disease relapse, offering new hope for patients battling this debilitating condition.
Researchers at OMT successfully created heritable, specific and permanent genetic modifications in rats using Zinc Finger Nuclease (ZFN) technology. This achievement paves the way for unrestricted development of a novel human monoclonal antibody platform.
Recent research suggests that monoclonal antibodies can stimulate both innate and adaptive immune responses, leading to more powerful control of cancer. This breakthrough could lead to the development of new treatments that alter antibodies to induce long-lasting immunity.
Researchers identified human monoclonal antibodies that can neutralize a broad range of influenza A viruses, including seasonal and pandemic flu strains. These antibodies offer potential for treatment and prevention of the flu during outbreaks or pandemics.
Researchers at Burnet Institute develop a potential new treatment for prostate cancer using a monoclonal antibody targeting the PIM-1 molecule, which plays a critical role in cell survival and proliferation. Laboratory models show significant inhibition of cancer cell growth, paving the way for clinical trials.
Researchers have developed a faster way to generate human monoclonal antibodies against influenza virus by tapping the immune system at peak powers. The method was tested on human volunteers and showed promising results, potentially finding broad application towards almost any infectious disease.
Research has established Neowater's ability to refine the standard hybridoma production process, leading to enhanced yields of human monoclonal antibodies. The novel nanoparticle-doped water also stimulates new membrane formation, improving cell growth and proliferation rates.
A report calls for improved monoclonal antibodies against solid tumors, as only 25 percent of approved therapies target these cancers. Researchers suggest manipulating the physical properties of a monoclonal antibody to improve treatment outcomes.
Researchers discovered a potential strategy for treating metastatic melanoma by combining an antibody with radiation, leveraging insights from studying a fungus that causes infection in people with AIDS. The treatment approach shows promise in inhibiting tumor growth and inducing regression in mice with small melanoma tumors.
The LEX System demonstrated the ability to produce monoclonal antibodies with homogeneous glycosylation structures, reducing production risks and costs. The system's success was shown through enhanced affinity for Fc receptors and increased effector function in oncology and autoimmune indications.
Researchers found that patients with symptomatic moderate asthma treated with anti-tumor necrosis factor alpha experienced significantly fewer disease exacerbations than those on placebo. The study also showed a significant decrease in diurnal variation in peak expiratory flow rate.
Researchers from Thomas Jefferson University have successfully created plant factories that produce antibodies against tumor cells, offering a potential alternative to expensive and traditional methods. The plant-made antibodies show similar effectiveness in inhibiting tumor growth as mammalian-made monoclonal antibodies.
Scientists have discovered a humanized monoclonal antibody that can boost survival rates of infected mice to 90% or higher. The antibody, produced by Macrogenics Inc., has potential utility against other infectious diseases and could help develop new treatments for related viruses like dengue fever.
A new nuclear medicine procedure has received preliminary approval for a clinical trial to diagnose inhalation anthrax in its earliest stages. The technique uses a 99mTc-labeled monoclonal antibody to detect the infection before other diagnostic tests can, enabling early treatment and reducing long-term antibiotic use.
Researchers identified two natural human antibodies that restored myelin sheath and promoted nervous system repair in mice with demyelinating diseases. The discovery holds promise for developing new treatments for conditions like multiple sclerosis.
Researchers at Rockefeller University have discovered an immune-cell mechanism that boosts the potency of therapeutic antibodies. The finding could lead to more effective cancer treatments by manipulating the interaction between antibodies and Fc receptors on immune cells.
MIT researchers have developed XenoMouse technology, which enables the amplification of atoms for genomics-based antibody drug development. This breakthrough could lead to the creation of fully human monoclonal antibody drugs with high affinity and reduced side effects.
Researchers have successfully developed an immunotoxin that kills over 99% of latent HIV-infected cells using a monoclonal antibody and ricin. The treatment targets CD45RO molecules found on the surface of memory T cells, which are difficult to target due to their low abundance.
Scientists at Johns Hopkins University have developed a new arsenal of medicines using monoclonal antibodies to prevent sexually transmitted diseases, gastrointestinal viruses, and the common cold. The antibodies can be produced in common field crops like corn and soy, making them potentially cheaper and more accessible.
Researchers from Johns Hopkins University have successfully evaluated soybean-produced antibodies that can prevent the spread of genital herpes virus. The findings suggest that these monoclonal antibodies could work well as a cheap and efficient topical lubricant for large-scale human populations.
Duke University researchers have developed a new treatment that significantly extends the survival of patients with glioblastoma multiforme, the most malignant brain cancer. The treatment involves injecting antibodies carrying radioactive Iodine-131 directly into the tumor cells, achieving a median survival time of about 56 weeks.
Researchers are exploring unmodified monoclonal antibodies, or 'naked mAbs', as a potential therapy for cancer. These antibodies can trigger programmed cell death in cancer cells, restoring control mechanisms that have gone awry in the disease.
Eukarion's antibody lipidation technology successfully blocks HIV-1 viral replication in human lymphocytic cells by targeting the Tat protein. The modified anti-Tat antibody is effective against laboratory and patient-strain viruses, offering new potential for cell-specific AIDS immunotherapies.
Researchers at the University of Pennsylvania School of Medicine have discovered a new antibody that targets the CXCR4 receptor, a molecule involved in HIV infection. The antibody, termed 12G5, has been shown to block some types of HIV from infecting cells and has enormous value for HIV investigators.